Septerna leverages its Native Complex™ Platform to recapitulate GPCRs with native structure, function, and dynamics to discover oral small-molecule therapeutics. Its pipeline is led by a PTH1R agonist program intended as a first-in-class oral treatment for hypoparathyroidism, and includes a program targeting TSHR plus earlier-stage assets. The company plans to advance the lead PTH1R program to clinical proof-of-mechanism and continue preclinical development of other programs. Septerna emphasizes addressing unmet needs versus existing therapies that require injections or only partially address PTH deficiency. The company was launched in 2022 and is based in South San Francisco, California. The recent financing strengthens its position as it transitions toward product development and builds a multi-product pipeline. Septerna uses its proprietary Native Complex™ Platform to recapitulate GPCRs with native structure, function, and dynamics outside of the cellular environment. The platform enables industrial-scale small-molecule drug discovery by applying novel screening technologies and structure-based drug design to GPCR targets. Septerna is advancing an emerging pipeline of GPCR-targeted small-molecule programs across multiple therapeutic areas and intends to industrialize the platform to access the broader GPCR superfamily. The company was launched in 2022 and is supported by a world-class scientific founder and advisor network that includes Nobel laureate Robert Lefkowitz. Septerna is based in South San Francisco, California. It announced a $100 million Series A financing to fund platform buildout and pipeline advancement.

Total raised

$250M

Funding rounds

2

Latest round

Series B

Latest activity

Jul 2023